Human CD20 / MS4A1 Full Length Protein, His Tag (Detergent) (SPR verified)

用户评价
货号-规格
价格
Qty.
CD0-H52H3-20ug
¥8190.00
CD0-H52H3-100ug
¥30450.00
CD0-H52H3-500ug
询价
合计0件 产品金额¥ 0

产品详情

  • 应用说明(Application)

    1. Immunization
    2. Affinity testing (SPR / BLI)
    3. Screening (ELISA)
  • 分子别名(Synonym)

    MS4A1, CD20, MS4A-1

  • 表达区间及表达系统(Source)

    Detergent Human CD20 Full Length Protein, His Tag (CD0-H52H3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).

    Predicted N-terminus: Met 1

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    CD20 Structure

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 35.2 kDa. The protein migrates as 40 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

    *The DDM/CHS buffer (Cat. No. DC-11) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Each full-length transmembrane protein is encapsulated by detergent micelle.

    2. Synthesis Process

      Through mild detergent micelle extraction, dedicated solubilization, and stringent affinity purification, we maximally retain the native transmembrane conformation of full-length transmembrane proteins throughout downstream purification. This workflow yields purified, detergent-solubilized proteins free of unrelated membrane impurities and exogenous scaffold proteins, with exceptional purity, accurate quantitation, and well-preserved biological activity—ideal for immunization, binding assays in antibody discovery and screening (ELISA) and affinity testing (SPR and BLI), etc.

  • 内毒素(Endotoxin)

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • 纯度(Purity)

    >85% as determined by SDS-PAGE.

  • 制剂(Formulation)

    This product is not suitable for cell based experiments due to cytotoxicity of DDM.
    DDM and CHS are INDISPENSABLE to keep membrane protein soluble and active, under no circumstances should you remove DDM and CHS.
    DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.
    If glycerol is not compatible with your application, remove glycerol just before the immediate experiment, and NEVER store glycerol-free protein solution.

    Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant.

    Contact us for customized product form or formulation.

  • 运输(Shipping)

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • 存储(Storage)

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

推荐产品

数据展示

  • 电泳(SDS-PAGE)

    CD20 SDS-PAGE

    Human CD20 Full Length Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 85% (With Star Ribbon Pre-stained Protein Marker).

  • 活性(Bioactivity)-ELISA

     CD20 ELISA

    Immobilized Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) at 5 μg/mL (100 μL/well) can bind Rituximab (Cat. No. CD0-M36) with a linear range of 0.4-3 ng/mL (QC tested).

    Protocol
  •  CD20 ELISA

    Immobilized Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) at 5 μg/mL (100 μL/well) can bind Ofatumumab with a linear range of 0.4-6 ng/mL (QC tested).

    Protocol
  •  CD20 ELISA

    Immobilized Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) at 5 μg/mL (100 μL/well) can bind Biosimilar of Obinutuzumab with a linear range of 1-8 ng/mL (Routinely tested).

    Protocol
  •  CD20 ELISA

    Immobilized Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3 at 1 μg/mL, add Glofitamab and then add Biotinylated Human CD3E&CD3G Heterodimer Protein, His,Avitag&Tag Free (Cat. No. CDG-H82W3) at 1 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).

    Protocol
  • 活性(Bioactivity)-SPR

     CD20 SPR

    MabThera® (Rituximab) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) with an affinity constant of 6.21 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (QC tested).

    Protocol
  •  CD20 SPR

    Ofatumumab captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) with an affinity constant of 9.63 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (QC tested).

    Protocol
  •  CD20 SPR

    Biosimilar of Obinutuzumab captured on CM5 chip via anti-human IgG Fc antibody can bind Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) with an affinity constant of 21.5 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

    Protocol
  •  CD20 SPR

    Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) captured on CM5 chip via Anti-His antibody can bind MabThera® (Rituximab) with an affinity constant of 0.921 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  • 活性(Bioactivity)-BLI

     CD20 BLI

    Loaded Rituximab on AHC Biosensor, can bind Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) with an affinity constant of 1.14 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  •  CD20 BLI

    Loaded Ofatumumab (Human IgG1) on AHC Biosensor, can bind Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) with an affinity constant of 0.968 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

用户评价
发表评论

背景介绍

A B-lymphocyte surface antigen expressed from pre-B to mature B cells, but absent on plasma cells. It functions as a calcium channel and is a validated immunotherapy target, famously exploited by rituximab for treating B-cell malignancies and autoimmune disorders.

前沿进展

 
药物研发进展
  • 英文全称:

    B-lymphocyte antigen CD20

  • 中文全称:

    B淋巴细胞抗原CD20

  • 种类:

  • 上市药物数量:

    33 详情

  • 临床药物数量:

    108 详情

  • 最高研发阶段:

    批准上市

联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 数据展示
  • 用户评价
  • 背景介绍